Recursion Pharmaceuticals, Inc. RXRX Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$559.78M+13.2% | -$644.76M+9.9% | -$715.54M-10.2% | -$649.13M-12.9% | -$574.78M-24.0% | ||
| $84.04M+0.4% | $83.7M+8.5% | $77.17M+21.9% | $63.33M+30.7% | $48.45M+32.8% | ||
| $97.38M-12.4% | $111.22M-5.9% | $118.24M+6.3% | $111.25M+9.5% | $101.62M+24.4% | ||
| -$320.95M+13.7% | -$371.81M+15.7% | -$441.17M-15.2% | -$383.03M+1.5% | -$388.83M-8.3% | ||
| $4.9M-24.3% | $6.47M-0.8% | $6.52M-39.8% | $10.84M+22.2% | $8.87M-35.2% | ||
| -$9.94M+41.1% | -$16.87M-106% | $259.83M+0.8% | $257.82M-0.6% | $259.44M-0.2% | ||
| $8.59M+1.9% | $8.43M+0.8% | $8.36M-1.9% | $8.52M+31.9% | $6.46M+45.5% | ||
| $477.54M-8.4% | $521.53M+30.3% | $400.17M+142% | $165.29M-50.0% | $330.75M+8.8% | ||
| $156.02M+3.4% | $150.9M-34.8% | $231.31M— | —— | —— | ||
| -$325.85M+13.9% | -$378.28M+15.5% | -$447.69M-13.7% | -$393.87M+1.0% | -$397.71M-6.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Recursion Pharmaceuticals, Inc. generate?
- Recursion Pharmaceuticals, Inc. (RXRX) generated -$321.0M in operating cash flow over the trailing twelve months.
- What is Recursion Pharmaceuticals, Inc.'s free cash flow?
- After $4.9M of capital expenditures, Recursion Pharmaceuticals, Inc.'s free cash flow was -$325.8M over the trailing twelve months, up 18.1% year over year.
- Where does Recursion Pharmaceuticals, Inc.'s cash flow data come from?
- Every line is extracted from Recursion Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
